OP0022 EFFECTS OF ETANERCEPT VS. SULFASALAZINE ON ACUTE INFLAMMATORY LESIONS AS DETECTED BY WHOLE BODY MRI IN EARLY AXIAL SPONDYLOARTHRITIS – A 48 WEEK RANDOMIZED CONTROLLED TRIAL

I.-H. Song 1,*K.-G. Hermann 2H. Haibel 1C. Althoff 1J. Listing 3B. Freundlich 4M. Rudwaleit 1J. Sieper 1

1Charité, Rheumatology, 2Charité, Radiology, 3German Rheumatism Center, Statistics, Berlin, Germany, 4Wyeth, Pharmaceuticals, Pennsylvanica, United States

 

Background:  

Objectives: To evaluate the potential of etanercept versus sulfasalazine to reduce active inflammatory lesions on magnetic resonance imaging (MRI) in active axial spondyloarthritis (SpA) of short symptom duration.

Methods: 76 patients with NSAID-refractory axial SpA were randomized to etanercept (ETA 25 mg given twice weekly subcutaneously; n= 40) or sulfasalazine (SULFA 2-3 g per day orally; n= 36) treatment over 48 weeks. All patients fulfilled the recently published ASAS-classification criteria for axial SpA, showed active inflammatory lesions (bone marrow edema) on whole-body MRI (wb-MRI) in either the sacroiliac joints (SIJ) or the spine and had a symptom duration of less than 5 years.  All patients underwent wb-MRI at week 0, 24 and 48. MRIs were scored by two radiologists, blinded for treatment arm and MRI time point, resulting in a score for the SIJ of between 0 and 24 and for the spine between 0 and 69. The primary endpoint was the reduction of active inflammatory lesions on wb-MRI, clinical outcome parameters were secondary endpoints.

Results: Patients’ characteristics were similar for the ETA group (mean age 35, 58% male, 85% HLA-B27 positive, mean symptom duration 2.6 years), and the SULFA group (mean age 33 years, 58% male, 78% HLA-B27 positive, mean symptom duration 3.0 years). At baseline, 92% of the patients showed active inflammatory lesions in the SIJ, 41% in the spine, but only 5% in the spine but not in the SIJ. According to the early disease stage, the mean score in the SIJ with 6.6 (standard deviation SD 5.9) out of 24 was relatively higher compared to a mean score of 1.8 (SD 3.3) out of 69 for the spine.

In the ETA group, there was a clear reduction of the SIJ score from 7.8 (SD 6.3) at baseline to 2.4 (SD 3.2) at week 48. After adjusting for the non-significantly different baseline MRI score, this reduction remained significantly (p=0.003) larger compared to the SULFA group: baseline 5.4 (SD 5.1) and 3.5 (SD 3.8) at week 48. The same was true when the reduction of inflammation in the spine was compared between the 2 groups: 2.3 (SD 3.5) vs 1.4 (SD 3.1) at screening and 1.0 (SD 2.1) vs 1.3 (SD 2.9) at week 48 for the ETA and SULFA groups, respectively (p=0.0024 for the difference). 50% of the patients reached ASAS clinical remission and 70% ASAS 40 response in the ETA group vs. 19% and 31% in the SULFA group at week 48, respectively. Of the 6 patients who became completely free of inflammation both in SIJ and spine in the ETA group all patients were also in clinical remission. In contrast, none of the 2 patients reaching remission on the SULFA group were free of inflammation as shown by wb-MRI.

Conclusion: In patients with early axial SpA active inflammatory lesions detected by whole body-MRI improved significantly greater in etanercept-treated versus sulfasalazine-treated patients. This effect correlated with a strong clinical response in the etanercept group.

 

Disclosure of Interest: None declared